Lupvindol Biosciences Limited Revenue

Pharmaceutical Manufacturing • 2389 Yorktown St, Oceanside, United States • 1-10 Employees

Lupvindol Biosciences Limited revenue & valuation

Annual revenue	$769,995
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$2,500,000
Total funding	$2,200,000

Key Contacts at Lupvindol Biosciences Limited

Hunter Land

Chief Executive Officer

Jennifer Love King

Director Of Regulatory Compliance

Mark Rogers

Marketing And Media Director

Company overview

Headquarters	2389 Yorktown St, Oceanside, New York 11572, US
Phone number	+441244445599
Website	lupvindol.com
NAICS	3254
Founded	2024
Employees	1-10
Socials

Lupvindol Biosciences Limited Email Formats

Lupvindol Biosciences Limited uses 1 email format. The most common is {2char} (e.g., {2char}@lupvindol.com), used 100% of the time.

Format	Example	Percentage
{2char}	{2char}@lupvindol.com	100%

About Lupvindol Biosciences Limited

Lupvindol Biosciences is a dynamic, cutting-edge company with robust intellectual property (IP) for combining the benefits of two existing FDA-approved pharmaceutical drugs— corticosteroids and CBD—into a fixed-dose combination formulation. This innovation aims to replace traditional inflammatory and auto immune regimens plagued by dose-limiting side effects, especially with prolonged use. Our data suggest enhanced efficacy and safety compared to steroids alone, at much lower doses. The Problem Maximizing Steroid Benefits While Minimizing Side Effects Corticosteroids are powerful tools in managing inflammatory pain and autoimmune conditions but come with a significant risk of side effects, particularly with long-term or high-dose use. These side effects can include osteoporosis, muscle atrophy, high blood pressure, diabetes, or psychiatric disturbances such as mood swings or psychosis. Physical changes like “moon face,” fat redistribution, or skin thinning are also common, alongside vision problems such as cataracts or glaucoma. The Solutions Patent Combination Therapy Lupvindol’s robust patent portfolio underpins the development of formulations combining CBD and corticosteroids in optimized ratios. CBD’s established potential as a steroid-sparing agent allows Lupvindol to address the adverse effects associated with long-term or high-dose steroid use, offering a safer alternative for managing inflammatory and autoimmune conditions.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Director

Entry

Employees by Department

Lupvindol Biosciences Limited has 3 employees across 3 departments.

Departments

Number of employees

Funding Data

Explore Lupvindol Biosciences Limited's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2025-01-23	3	$2,200,000

Funding Insights

$2,200,000

Total funding amount

$2,200,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

Lupvindol Biosciences Limited is located in 2389 Yorktown St, Oceanside, US.

You can reach Lupvindol Biosciences Limited at +441244445599.

Lupvindol Biosciences Limited generates an estimated annual revenue of $769,995. This revenue figure reflects the company's market position and business performance in its industry.

Lupvindol Biosciences Limited has an estimated valuation of $2,500,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Lupvindol Biosciences Limited was founded in 2024, making it 2 years old. The company has established itself as a significant player in its industry over this time.

Lupvindol Biosciences Limited has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Lupvindol Biosciences Limited has raised a total of $2,200,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.